Splenectomy for end-stage chronic lymphocytic leukemia.
Between February 1980 and December 1985, splenectomies were performed in 13 patients with advanced (Stage III and IV) chronic lymphocytic leukemia (CLL). Patients had advanced disease for a median of 32 months at the time of splenectomy and all were refractory to chemotherapy. All patients were anemic with a median hematocrit of 27.5%; nine patients were thrombocytopenic with a median platelet count of 46,000/microliter. There was no surgical mortality and minimal morbidity. Median hematocrit was 35% at 1 month and 6 months postsplenectomy. Median platelet count in previously thrombocytopenic patients was 261,000/microliter at 1 month and 177,000/microliter at 6 months postsplenectomy. Median survival postsplenectomy in this advanced patient group was 24 months with four patients surviving more than 30 months. Splenectomy is a valuable adjunct to the management of end-stage CLL.
D000206:Actuarial Analysis; D000368:Aged; D000740:Anemia / Q000601:surgery; D005260:Female; D006400:Hematocrit; D006801:Humans; D007945:Leukemia, Lymphoid / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010976:Platelet Count; D013156:Splenectomy; D013921:Thrombocytopenia / Q000601:surgery